Insights into the function of DNA Topoisomerase VI (Topo VI) may provide a springboard for drug discovery and crop protection ...
GlobalData on MSN4mon
FDA grants IND clearance for Innate Pharma’s solid tumour trialIPH4502 is a topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 solid tumours. The Phase I study, set ...
Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...
GlobalData on MSN15d
Innate Pharma doses first patient in Nectin-4 ADC trialThe Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal cells unharmed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback